Comments on: Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

Comments on: Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) https://enterabio.com/news/entera-bio-announces-new-data-supporting-further-development-of-a-proprietary-first-in-class-oral-long-acting-pth-tablet-for-patients-with-hypoparathyroidism-eb612-program/ Global Leader in Oral Delivery of Therapeutic Proteins Mon, 22 Dec 2025 16:35:19 +0000 hourly 1 https://wordpress.org/?v=6.8.1